Planning operations before market launch for balancing time-to-market and risks in pharmaceutical supply chains

International Journal of Production Economics

Volumn 161, Issue , 2015, Pages 129-139

  Hansen, Klaus Reinholdt Nyhuus ^a   Grunow, Martin ^b  

^a TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^b TUM SCHOOL OF MANAGEMENT   (Germany)

Author keywords

Market launch planning; New product introduction; Regulatory affairs; Two stage stochastic programming

Indexed keywords

COMMERCE; CONCURRENT ENGINEERING; DECISION SUPPORT SYSTEMS; STOCHASTIC MODELS; STOCHASTIC PROGRAMMING; STOCHASTIC SYSTEMS; SUPPLY CHAINS;

MARKET LAUNCH; NEW PRODUCT INTRODUCTIONS; PHARMACEUTICAL SECTOR; PHARMACEUTICAL SUPPLY CHAINS; QUANTITATIVE METHODOLOGY; REGULATORY AFFAIRS; TWO-STAGE STOCHASTIC MODELS; TWO-STAGE STOCHASTIC PROGRAMMING;

LIFE CYCLE;

EID: 84921743662     PISSN: 09255273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpe.2014.10.010     Document Type: Article

References (31)

1. R. Abt, M. Borja, M.M. Menke, and J.P. Pezier The dangerous quest for certainty in market forecasting Long Range Plan. 12 2 1979 52 62
2. F.M. Bass A new product growth for model consumer durables Manag. Sci. 15 5 1969 215 227
3. H.H. Bauer, and M. Fischer Product life cycle patterns for pharmaceuticals and their impact on R&D profitability of late mover products Int. Bus. Rev. 9 6 2000 703 725
4. Y. Boulaksil, M. Grunow, and J.C. Fransoo Capacity flexibility allocation in an outsourced supply chain with reservation Int. J. Prod. Econ. 129 1 2011 111 118
5. S.B. Cantor Clinical applications in the decision analysis literature Decis. Anal. 1 1 2004 25 28
6. A.C. Cook Forecasting for the Pharmaceutical Industry: Models for New Product and In-Market Forecasting and How to Use Them 2006 Gower Publishing Limited Hampshire, England
7. P.M. Danzon, Y.R. Wang, and L. Wang The impact of price regulation on the launch delay of new drugs - Evidence from twenty-five major markets in the 1990s Health Econ. 14 3 2005 269 292
8. J.A. DiMasi The value of improving the productivity of the drug development process - Faster times and better decisions PharmacoEconomics 20 Suppl 3 2002 1 10
9. EFPIA 2010. Patients W.A.I.T. Indicator, European Federation of Pharmaceutical Industries and Associations, Brussels, Belgium.
10. K.M. Eisenhardt Building theories from case-study research Acad. Manag. Rev. 14 4 1989 532 550
11. L. Garattini, D. Cornago, and P. De Compadri Pricing and reimbursement of in-patent drugs in seven European countries: a comparative analysis Health Policy 82 3 2007 330 339
12. J. Gjerdrum, N. Shah, and L.G. Papageorgiou New product introduction supply chain planning O.-P. Hilmola, Contemporary Research Issues in New Product Introduction 2001 University of Vaasa Publications Finland 25 49
13. V. Goel, and I.E. Grossmann A Class of stochastic programs with decision dependent uncertainty Math. Program. 108 2-3 2006 355 394
14. M. Grunow, H.O. Günther, and G. Yang Plant co-ordination in pharmaceutics supply networks OR Spectr. 25 1 2003 109 141
15. G.J. Hahn, and H. Kuhn Simultaneous investment, operations, and financial planning in supply chains: a value-based optimization approach Int. J. Prod. Econ. 140 2 2012 559 569
16. Hansen, K.R.N., Grunow, M., 2010. Challenges in shortening new product introduction in the pharmaceutical industry. In: Proceedings of the European Operations Management Association Conference (EUROMA 2010), Porto, Portugal, June 6-9, 2010, NPM8, pp. 1-10
17. K.R.N. Hansen, and M. Grunow Modelling ramp-up curves to reflect learning: Improving capacity planning in secondary pharmaceutical production Int. J. Prod. Res. 2015 http://dx.doi.org/10.1080/00207543.2014.998788
18. T.H. Ho, S. Savin, and C. Terwiesch Managing demand and sales dynamics in new product diffusion under supply constraint Manag. Sci. 48 2 2002 187 206
19. D. Jain, V. Mahajan, and E. Muller An approach for determining optimal product sampling for the diffusion of a new product J. Prod. Innov. Manag. 12 2 1995 124 135
20. D.L. Keefer, C.W. Kirkwood, and J.L. Corner Perspective on decision analysis applications, 1990-2001 Decis. Anal. 1 1 2004 5 38
21. S. Kumar, and J.M. Swaminathan Diffusion of innovations under supply constraints Oper. Res. 51 6 2003 866 (879+1004)
22. J.M. Laínez, E. Schaefer, and G.V. Reklaitis Challenges and opportunities in enterprise-wide optimization in the pharmaceutical industry Comput. Chem. Eng. 47 1 2012 19 28
23. M.S. Lipsky, and L.K. Sharp From idea to market: the drug approval process J. Am. Board.Fam. Med. 14 5 2001 362
24. O. Özer, and O. Uncu Competing on time: An integrated framework to optimize dynamic time-to-market and production decisions Prod. Oper. Manag. 22 3 2013 473 488
25. PhRMA 2012. Pharmaceutical Industry Profile 2012, Pharmaceutical Research and Manufacturers of America, Washington, DC.
26. B. Poland, and R. Wada Combining drug-disease and economic modelling to inform drug development decisions Drug Discov. Today 6 22 2001 1165 1170
27. C.L. Rossetti, R. Handfield, and K.J. Dooley Forces, trends, and decisions in pharmaceutical supply chain management Int. J. Phys. Distrib. Logist. Manag. 41 6 2011 601 622
28. N. Shah Pharmaceutical supply chains: key issues and strategies for optimisation Comput. Chem. Eng. 28 6-7 2004 929 941
29. H. Stefansson, and N. Shah Multi-scale planning and scheduling in the pharmaceutical industry Comput. Aided Chem. Eng. 52 12 2005 4133 4149
30. J.S. Stonebraker, and D.L. Keefer Modeling potential demand for supply-constrained drugs: a new hemophilia drug at bayer biological products Oper. Res. 57 1 2009 19 31
31. A. Sundaramoorthy, and I.A. Karimi Planning in pharmaceutical supply chains with outsourcing and new product introductions Indus. Eng. Chem. Res. 43 26 2004 8293 8306